Epitomics, Inc. and University of California, Davis, Complete Star Program for High-Throughput Measurement of Antibody-Antigen Interactions
BURLINGAME, Calif., Dec. 21, 2011 /PRNewswire/ -- Epitomics, Inc., a California based biotech company, announced today that they have successfully completed a Star Program in collaboration with the University of California, Davis, which has resulted in the application of a new, advanced antibody assay technique, a label-free optical microarray detection platform, for high-throughput measurements of antibody-antigen interactions. Over the course of the project, more than 100 rabbit monoclonal antibodies (RabMAbs) raised against clinical cancer biomarkers were analyzed and determined to possess affinities ranging from 10-9 to 10-13 M, with an average of 10-10 M. The affinity values measured using this label-free optical microarray detection process were found to be consistent with those measured using the established BIAcore technology, based on a random sampling of the RabMAb population.
"I am very excited about our new technology which can provide consistent results compared to the established BIAcore technology but in a high throughput manner. I am also impressed with high affinities of RabMAbs," said Dr. Xiangdong Zhu, a Professor in Physics at the University of California, Davis, who was the inventor of the label-free optical microarray detection technology used in the program.
"It is widely accepted that rabbits produce higher affinity antibodies than mice, but this had not previously been demonstrated with a large population of monoclonal antibodies. With the availability of this novel technology, we were able to demonstrate that RabMAbs have consistently high affinities through the measurement of a large collection of RabMAbs," said Dr. Guo-Liang Yu, CEO, Epitomics, Inc.
About Epitomics
Epitomics, Inc., an emerging biotechnology company, is dedicated to developing breakthrough monoclonal antibody technology for research and diagnostic applications. The company utilizes a unique and proprietary RabMAb® (Rabbit Monoclonal Antibody) technology which produces antibodies with superior binding affinity, specificity and bioactivity both in vitro and in vivo. Epitomics, Inc. is headquartered in Burlingame, California, and operates wholly owned subsidiaries in Hong Kong and Hangzhou, the People's Republic of China. For more information about Epitomics, please visit www.epitomics.com.
SOURCE Epitomics, Inc.
